Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vistagen Therapeutics, Inc. - Common Stock (NQ:VTGN)

0.5999 -0.0007 (-0.12%)
Streaming Delayed Price Updated: 1:29 PM EDT, Apr 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vistagen Therapeutics, Inc. - Common Stock

< Previous 1 2
...
9 10 11 12 13 14 15 16 Next >
News headline image
Nasdaq Drops Around 200 Points; Hanger Shares Spike Higher ↗
U.S. stocks traded lower midway through trading, with the Nasdaq Composite dropping around 200 points on Friday. 
Via Benzinga
News headline image
This Consumer Defensive Stock Is Trading Higher By Around 49%, Here Are 46 Stocks Moving In Friday's Mid-Day Session ↗
Gainers Pagaya Technologies Ltd. (NASDAQ: PGY) shares gained 93% to $10.32. Pagaya Technologies is expected to announce its Q2 earnings on August 16, 2022. 
Via Benzinga
News headline image
VistaGen Therapeutics (VTGN) Stock Plunges on Disappointing Clinical Data ↗
VistaGen Therapeutics (VTGN) stock is falling hard on Friday after the company reported poor results from a Phase 3 study. 
Via InvestorPlace
News headline image
VistaGen Says Data From Late-Stage Anxiety Study 'Not Consistent' With Prior Positive Phase 2 Study ↗
 
Via Benzinga
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Topline Results from PALISADE-1 Phase 3 Clinical Trial for PH94B
Via Investor Brand Network
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For July 22, 2022 ↗
Upgrades 
Via Benzinga
News headline image
Daily Biotech Pulse: VistaGen's Anxiety Study Fails, Silverback To Merge With Firm Developing EpiPen Alternative, Setback For Liminal's Lead Asset ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
VistaGen Announces Topline Results from PALISADE-1 Phase 3 Clinical Trial for Investigational Drug PH94B
From VistaGen Therapeutics, Inc.
Via Business Wire
News headline image
Stocks That Hit 52-Week Lows On Tuesday ↗
  Tuesday saw 37 companies set new 52-week lows. 
Via Benzinga
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) to Participate at 2022 Concordia Americas Summit; CEO and US Surgeon General to Discuss Mental Health Crisis
Via Investor Brand Network
News headline image
Stocks That Hit 52-Week Lows On Friday ↗
  On Friday, 137 stocks made new 52-week lows. 
Via Benzinga
News headline image
VistaGen CEO Joins U.S. Surgeon General to Discuss Mental Health Crisis in America at the 2022 Concordia Americas Summit
From VistaGen Therapeutics, Inc.
Via Business Wire
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) to Participate at William Blair Biotech Focus Conference 2022
Via Investor Brand Network
News headline image
VistaGen to Participate at William Blair Biotech Focus Conference 2022
From VistaGen Therapeutics, Inc.
Via Business Wire
News headline image
Looking Into VistaGen Therapeutics's Return On Capital Employed ↗
Benzinga Pro data, VistaGen Therapeutics (NASDAQ:VTGN) reported Q4 sales of $38.90 thousand. Earnings fell to a loss of $16.69 million, resulting in a 58.41% decrease from last quarter. 
Via Benzinga
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Corporate Update, FY 2022 Results
Via Investor Brand Network
News headline image
Stocks That Hit 52-Week Lows On Tuesday ↗
During Tuesday's session, 539 stocks hit new 52-week lows. 
Via Benzinga
News headline image
VistaGen Therapeutics Reports Fiscal Year 2022 Financial Results and Provides Corporate Update
From VistaGen Therapeutics, Inc.
Via Business Wire
News headline image
Earnings Scheduled For June 23, 2022 ↗
Companies Reporting Before The Bell • Jerash Holdings (US) (NASDAQ:JRSH) is projected to report quarterly earnings at $0.07 per share on revenue of $30.14 million. 
Via Benzinga
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Completes PH94B PALISADE-1 Phase 3 Clinical Study for Acute Treatment of SAD
Via Investor Brand Network
News headline image
Earnings Preview For VistaGen Therapeutics ↗
VistaGen Therapeutics (NASDAQ:VTGN) is set to give its latest quarterly earnings report on Thursday, 2022-06-23. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
News headline image
VistaGen Announces Completion of PALISADE-1 Phase 3 Clinical Study of PH94B for the Acute Treatment of Social Anxiety Disorder
From VistaGen Therapeutics, Inc.
Via Business Wire
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Schedules Webcast to Announce FY 2022 Results
Via Investor Brand Network
News headline image
VistaGen Therapeutics to Report Fiscal Year 2022 Financial Results on June 23, 2022
From VistaGen Therapeutics, Inc.
Via Business Wire
News headline image
Stocks That Hit 52-Week Lows On Wednesday ↗
Wednesday's session saw 269 companies set new 52-week lows. 
Via Benzinga
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) to Present Clinical Trial Abstract at ASCP Annual Meeting
Via Investor Brand Network
News headline image
Stocks That Hit 52-Week Lows On Monday ↗
During Monday's trading, 1214 companies set new 52-week lows. 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Friday ↗
On Friday, 422 stocks made new 52-week lows. 
Via Benzinga
News headline image
VistaGen to Present PH94B Exploratory Phase 2A Research Program for Adjustment Disorder with Anxiety at American Society for Clinical Psychopharmacology Annual Meeting
From VistaGen Therapeutics, Inc.
Via Business Wire
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Participation in Top Investor Conferences
Via Investor Brand Network
< Previous 1 2
...
9 10 11 12 13 14 15 16 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.